Zai Lab Limited (ZLAB)
| Previous close | 34.22 |
| Open | 34.33 |
| Bid | 33.72 x 1300 |
| Ask | 33.78 x 800 |
| Day's range | 33.58 - 35.00 |
| 52-week range | 22.51 - 178.91 |
| Volume | |
| Avg. volume | 628,190 |
| Market cap | 3.332B |
| Beta (5Y monthly) | 1.21 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.84 |
| Earnings date | 09 Aug 2022 - 15 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 98.08 |
- GlobeNewswire
Zai Lab Announces Primary Listing on the Main Board of The Stock Exchange of Hong Kong Limited
– First company to Convert from Secondary to Primary Listing Status in Hong Kong – Our dual Primary Listing on the Nasdaq and Hong Kong Stock Exchange provides greater access for investors SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it has completed its voluntary conversion of its secondary listing status to a p
- GlobeNewswire
Zai Lab Announces Breakthrough Therapy Designations Granted for Repotrectinib in China
-- Breakthrough Therapy Designations granted for ROS1-positive non-small cell lung cancer (NSCLC) patients pretreated with one prior line of ROS1 tyrosine kinase inhibitor (TKI) with or without prior chemotherapy -- Potential best-in-class therapy for ROS1-positive metastatic NSCLC and NTRK-positive advanced solid tumors SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, g
- Simply Wall St.
What Kind Of Investors Own Most Of Zai Lab Limited (NASDAQ:ZLAB)?
If you want to know who really controls Zai Lab Limited ( NASDAQ:ZLAB ), then you'll have to look at the makeup of its...
